Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Hematologic Neoplasms 3Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Granuloma, Plasma Cell 1Glioblastoma 1

Interventions

Paclitaxel 2Azacitidine 2temsirolimus 1sargramostim 1ruxolitinib 1rucaparib 1pembrolizumab 1fludarabine 1ceritinib 1cc-486 1carboxyamido-triazole 1bemcentinib 1acalabrutinib 1abiraterone 1Uncertainty 1Thalidomide 1Temozolomide 1Sorafenib 1Quality of Life 1Psychosocial Intervention 1Patient Reported Outcome Measures 1Oxaliplatin 1O(6)-benzylguanine 1Molecular Diagnostic Techniques 1Leucovorin 1Lenalidomide 1Interleukin-2 1Interleukin-15 1Injections 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × ceritinib × Other hematologic neoplasm × Clear all
NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡